Skip Navigation

Publicaciones covid-9

Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection

Philip J. M. Brouwer, Mitch Brinkkemper, Pauline Maisonnasse, Nathalie Dereuddre-Bosquet, Marloes Grobben, Mathieu Claireaux, Marlon de Gast, Romain Marlin, Virginie Chesnais, Ségolène Diry, View ORCID ProfileJoel D. Allen, Yasunori Watanabe, Julia M. Giezen, Gius Kerster, Hannah L. Turner, Karlijn van der Straten, Cynthia A. van der Linden, Yoann Aldon, Thibaut Naninck, Ilja Bontjer, Judith A. Burger, Meliawati Poniman, Anna Z. Mykytyn, Nisreen M. A. Okba, Edith E. Schermer, Marielle J. van Breemen, Rashmi Ravichandran, Tom G. Caniels, Jelle van Schooten, Nidhal Kahlaoui, Vanessa Contreras, Julien Lemaître, Catherine Chapon, Raphaël Ho Tsong Fang, Julien Villaudy, Kwinten Sliepen, Yme U. van der Velden, Bart L. Haagmans, Godelieve J. de Bree, Eric Ginoux, Andrew B. Ward, Max Crispin, Neil P. King, Sylvie van der Werf, Marit J. van Gils, Roger Le Grand, Rogier W. Sanders
?  Evaluación: (not yet rated)
Resumen

The SARS-CoV-2 pandemic is continuing to disrupt personal lives, global healthcare systems and economies. Hence, there is an urgent need for a vaccine that prevents viral infection, transmission and disease. Here, we present a two-component protein-based nanoparticle vaccine that displays multiple copies of the SARS-CoV-2 spike protein. Immunization studies show that this vaccine induces potent neutralizing antibody responses in mice, rabbits and cynomolgus macaques. The vaccine-induced immunity protected macaques against a high dose challenge, resulting in strongly reduced viral infection and replication in upper and lower airways. These nanoparticles are a promising vaccine candidate to curtail the SARS-CoV-2 pandemic.

Procedencia del autor
Texto completo
Tipo de documento
Especialidad(es)
Publicado en el sitio 2021-01-30 17:37:13

Comentarios

(aún no hay comentarios disponibles para este recurso)